Literature DB >> 7726316

Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.

K S Kendler1, M McGuire, A M Gruenberg, D Walsh.   

Abstract

OBJECTIVE: The authors sought to assess whether the DSM-III-R category of schizoaffective disorder differs meaningfully from schizophrenia and affective illness in clinical features, outcome, and familial psychopathology. In addition, the authors evaluated the validity of two proposed subtyping systems for schizoaffective disorder: 1) bipolar versus depressive (based on presence or absence of a full manic syndrome in the past) and 2) good versus poor interepisode recovery.
METHOD: In the epidemiologically based Roscommon Family Study, index probands with diagnoses of schizophrenia or affective illness were selected from a case registry. Personal interviews were conducted with 88% of traceable, living probands and 86% of traceable, living first-degree relatives.
RESULTS: Probands with schizoaffective disorder differed significantly from both those with schizophrenia and those with affective illness on lifetime psychotic symptoms as well as on outcome and negative symptoms assessed as follow-up. Relatives of probands with schizoaffective disorder had significantly higher rates of affective illness than relatives of schizophrenic probands and significantly higher rates of schizophrenia than relatives of probands with affective illness. Probands with bipolar and depressive schizoaffective disorder did not differ substantially with respect to psychotic symptoms, negative symptoms, outcome, or family history. Schizoaffective disorder probands with good interepisode recovery had fewer negative symptoms and a better outcome than those with poor recovery, but there were no significant differences in family history. Both the epidemiologic and family data are consistent with the hypothesis that schizoaffective disorder results from the co-occurrence of a high liability to both schizophrenia and affective illness.
CONCLUSIONS: On the basis of the validators examined, DSM-III-R criteria for schizoaffective disorder define a syndrome that differs meaningfully from both schizophrenia and affective illness. The division of schizoaffective disorder into bipolar and depressive subtypes was, however, not validated. The separation of schizoaffective disorder into subtypes based on level of interepisode recovery defined subtypes that differed clinically but not with respect to familial psychopathology.

Entities:  

Mesh:

Year:  1995        PMID: 7726316     DOI: 10.1176/ajp.152.5.755

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  20 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

2.  Association of stigma, self-esteem, and symptoms with concurrent and prospective assessment of social anxiety in schizophrenia.

Authors:  Paul H Lysaker; Philip T Yanos; Jared Outcalt; David Roe
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-04

3.  Specificity of psychosis, mania and major depression in a contemporary family study.

Authors:  C L Vandeleur; K R Merikangas; M-P F Strippoli; E Castelao; M Preisig
Journal:  Mol Psychiatry       Date:  2013-10-15       Impact factor: 15.992

4.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

5.  A twin study of schizoaffective-mania, schizoaffective-depression, and other psychotic syndromes.

Authors:  Alastair G Cardno; Frühling V Rijsdijk; Robert M West; Irving I Gottesman; Nick Craddock; Robin M Murray; Peter McGuffin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-12-27       Impact factor: 3.568

Review 6.  The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

Authors:  John H Krystal; D Cyril D'Souza; Jürgen Gallinat; Naomi Driesen; Anissa Abi-Dargham; Ismene Petrakis; Andreas Heinz; Godfrey Pearlson
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

7.  The New York High-Risk Project. Prevalence and comorbidity of axis I disorders in offspring of schizophrenic parents at 25-year follow-up.

Authors:  L Erlenmeyer-Kimling; U H Adamo; D Rock; S A Roberts; A S Bassett; E Squires-Wheeler; B A Cornblatt; J Endicott; S Pape; I I Gottesman
Journal:  Arch Gen Psychiatry       Date:  1997-12

Review 8.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder.

Authors:  Daniel H Mathalon; Ralph E Hoffman; Todd D Watson; Ryan M Miller; Brian J Roach; Judith M Ford
Journal:  Front Hum Neurosci       Date:  2010-01-29       Impact factor: 3.169

10.  Bridging the gap between schizophrenia and psychotic mood disorders: Relating neurocognitive deficits to psychopathology.

Authors:  Matthew J Smith; Deanna M Barch; John G Csernansky
Journal:  Schizophr Res       Date:  2008-09-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.